Johnson & Johnson — Deal History & Benchmarks
Market Analysis
Johnson & Johnson has been involved in 16 transactions totaling $42.8B across Neurology & CNS, Immunology & Autoimmune, Hematology, Gastroenterology, Dermatology, Infectious Disease, Oncology. As both a licensor and licensee, they have demonstrated a preference for licensing partnerships.
Key transactions include Intra-Cellular ($14.6B, 2025), Momenta Pharmaceuticals ($6.5B, 2020), J&J ($3.2B, 2024).
Their deal activity is concentrated in Neurology & CNS (19%) with Small Molecule and Monoclonal Antibody assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Johnson & Johnson done?
What is Johnson & Johnson's typical deal structure?
What therapeutic areas does Johnson & Johnson focus on?
How has Johnson & Johnson's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.